Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for Kyverna Therapeutics in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.66) per share for the quarter, up from their previous estimate of ($0.78). HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($2.78) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.74) EPS, Q3 2027 earnings at ($0.74) EPS, Q4 2027 earnings at ($0.54) EPS and FY2027 earnings at ($2.79) EPS.
Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. reduced their target price on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research note on Wednesday, May 13th. Wall Street Zen cut Kyverna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $30.00.
Check Out Our Latest Stock Analysis on Kyverna Therapeutics
Kyverna Therapeutics Price Performance
Shares of NASDAQ KYTX opened at $8.08 on Friday. The stock has a fifty day moving average price of $8.06 and a 200 day moving average price of $8.44. Kyverna Therapeutics has a 1-year low of $3.27 and a 1-year high of $13.67. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The company has a market cap of $499.67 million, a PE ratio of -2.75 and a beta of 1.93.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.05.
Institutional Trading of Kyverna Therapeutics
A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Kyverna Therapeutics in the second quarter valued at $27,931,000. AIGH Capital Management LLC acquired a new position in shares of Kyverna Therapeutics during the 2nd quarter worth $24,911,000. Adage Capital Partners GP L.L.C. acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $15,667,000. Balyasny Asset Management L.P. purchased a new position in Kyverna Therapeutics during the 4th quarter valued at about $9,220,000. Finally, Propel Bio Management LLC purchased a new position in Kyverna Therapeutics during the 4th quarter valued at about $6,267,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.
Kyverna Therapeutics Company Profile
(
Get Free Report)
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
